New Biomarkers to

Accelerate Drug Development & Track Disease Progression

​

AI driven In-cell Molecular Analytics and Diagnostics

​

Esya's DNA probes can ratiometrically quantify ions within endocytic organelles such as Endosomes & Lysosomes, for diseases such as COVID-19, Lysosomal Storage Disorders & Alzheimer's Disease

Innovative Technology

In-Cell Ion measurement

Our nanodevices are DNA sensors made of DNA filaments knitted-together to hold measuring devices to ratiometrically quantify ions for specific chemicals:

• I-switch (pH)

• Clensor (Cl-)

• CalipHluor (Ca2+ & pH)

• ChloropHore (pH & Cl-)

• Enzyme detection

Quantifiable Measurement within Organelles

Different versions of our nanodevices target different organelles for precision measurement within live cells:

• Early endosome

• Late endosome

• Lysosome

• Recycling endosome

• Golgi

Esya's non invasive Patient driven biomarkers

By chemically profiling various biological markers, such as lysosomal ion signatures, our technologies can help decode the underpinnings of a number of different diseases, as well as test potential drug treatments and therapies.

Subcellular Imaging

• Patient Cells either normal or manifesting a disease

• Esya's proprietary Probes added to the cell culture, either individually or with High throughput screening

• Cells imaged for ratiometric analysis

Data Science-Based, AI-Enabled Analytics

• Imaged cells analysed using custom built Esya Analytics

• Esya's Analytics are proprietary machine learning based Algorithms enhanced with Big data

• In-cell reaction and biomarker reports with quantifiable measurements

Disease Modeling and Therapeutic Insights

• Measure and monitor disease progression

• Non-invasively quantify a patient's response to a treatment

• Reveal the efficacy and specificity of a drug

• Phenotype diseases to discover new therapeutics

Media & Press Updates